Medical Developments International Limited · ASX:MVP
Medical Developments International — Shareholder Meeting (October 2024)
26 slides from Medical Developments International's shareholder meeting presentation, Oct 24, 2024
Slide 1: FY24 Annual General Meeting
ASX:MVP FY24 For personal use only ANNUAL GENERAL MEETING 24 OCTOBER 2024
Slide 2: Important notice and disclaimer
Important notice and disclaimer This presentation contains summary information about Medical Developments International Limited (ACN 106340667) and its related bodies corporate (together, MVP) and MVP’s activities as at the date of this presentation. It is information given in summary form only and
Slide 3: Important notice and disclaimer
Important notice and disclaimer Factors that could cause actual results to differ materially include: • the success of research and development activities (including clinical trials); • decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label
Slide 4: Gordon Naylor, Company Chair
For personal use only Gordon Naylor Company Chair 4
Slide 5: Your Board
Your Board For personal use only Gordon Naylor Dr. Russell Basser Richard Betts Christine Emmanuel- Leon Hoare Mary Sontrop Company Chair Independent Non-executive Independent Non-executive Donnelly Independent Non-executive Independent Non-executive Director Director Independent Non-executive Direc
Slide 6: How to ask a question
How to ask a question To ask a written question select the Q & A icon For personal use only Select the topic your question relates to from the drop-down list Type your question in the text box and press the send button To ask a verbal question follow the instructions below the broadcast window. 6
Slide 7: How to vote
How to vote When the poll is open, select the vote icon at the top of the screen For personal use only To vote, select either For, Against or Abstain You will see a vote confirmation To change or cancel your vote “click here to change your vote” at any time until the poll is closed 7
Slide 8: Positive momentum in FY24
For personal use only Positive momentum in FY24 8
Slide 9: CEO Brent MacGregor
For personal use only 9 CEO Brent MacGregor
Slide 10: Highlights
Highlights Financial performance strongly improved, positive momentum to continue FY24 results • Group revenue of $33.2m (+3%) with improved results in Pain Management and Respiratory Margins, earnings • Gross margin2 expansion of 5ppts to 74% For personal use only • Significant operating cost reduc
Slide 11: FY25 priorities
FY25 priorities Deliver improved earnings and cashflow and accelerate product penetration FY25 strategic priorities For personal use only Improve margins through pricing and operational efficiency Accelerate penetration of Penthrox in Australia Grow Penthrox in global markets Drive continued growth
Slide 12: Questions
For personal use only 12 Questions
Slide 13: Formal Business
For personal use only 13 Formal Business
Slide 14: Adoption of Remuneration Report
Resolution 1 For personal use only “That the Remuneration Report for the year ended 30 June 2024 as set out in the Company’s Annual Report for the year ended 30 June 2024 be adopted.” 14
Slide 15: Proxy results 1
Resolution 1: Proxy results For Against Open Abstain For personal use only No. Of Shares 14,803,851 578,364 254,263 68,940 % of Total 94.68% 3.70% 1.62% N/A Proxies 15
Slide 16: Re-election of Gordon Naylor
Resolution 2 For personal use only “That pursuant to the Company’s Constitution and for all other purposes, the members of the Company approve the re-election of Mr Gordon Naylor as a Non-Executive Director of the Company, who pursuant to clause 12.4 of the Company’s Constitution is retiring by rota
Slide 17: Proxy results 2
Resolution 2: Proxy results For Against Open Abstain For personal use only No. Of Shares 10,374,046 371,950 280,985 5,425,481 % of Total 94.08% 3.37% 2.55% N/A Proxies 17
Slide 18: Re-election of Richard Betts
Resolution 3 For personal use only “That pursuant to the Company’s Constitution and for all other purposes, the members of the Company approve the re-election of Mr Richard Betts as a Non-Executive Director of the Company, who pursuant to clause 12.4 of the Company’s Constitution is retiring by rota
Slide 19: Proxy results 3
Resolution 3: Proxy results For Against Open Abstain For personal use only No. Of Shares 16,723,999 396,559 284,690 65,763 % of Total 96.08% 2.28% 1.64% N/A Proxies 19
Slide 20: Ratification of share issue
Resolution 4 For personal use only “That, for the purpose of ASX Listing Rule 7.4 and for all other purposes, Shareholders approve and ratify the issue of 14,605,263 Shares to certain institutional, professional and sophisticated investors on the terms and conditions more fully described in the Expl
Slide 21: Proxy results 4
Resolution 4: Proxy results For Against Open Abstain For personal use only No. Of Shares 9,479,718 580,985 280,991 6,013,763 % of Total 91.66% 5.62% 2.72% N/A Proxies 21
Slide 22: Approval of additional 10% placement capacity
Resolution 5 “That pursuant to and in accordance with ASX Listing Rule 7.1A and for all other purposes, Shareholders For personal use only approve the increase in the capacity of the Company to issue equity securities up to 10% of the issued capital of the Company (at the time of the issue) calculat
Slide 23: Proxy results 5
Resolution 5: Proxy results For Against Open Abstain For personal use only No. Of Shares 10,798,422 6,360,118 276,176 62,859 % of Total 61.93% 36.48% 1.59% N/A Proxies 23
Slide 24: Proportional takeover provisions amendment
Resolution 6 “That pursuant to sections 136(2) and 648G(4) of the For personal use only Corporations Act and for all other purposes, the members of the Company approve the amendment of the Company’s Constitution by re-inserting Rules 7.5.2 and 7.8, being the proportional takeover provisions of the C
Slide 25: Proxy results
Resolution 5: Proxy results For Against Open Abstain For personal use only No. Of Shares 16,534,246 620,213 280,085 63,031 % of Total 94.83% 3.56% 1.61% N/A Proxies 25
Slide 26: Conclusion
For personal use only 26 Conclusion
Medical Developments International — Shareholder Meeting (October 2024) on 6ix